CDKN2A p16 Expression

CI-VAR-00005037Explore in graph →CIViC 272

Curated evidence

Evidence by cancer (11 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–11 of 11 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Head and Neck Squamous Cell Carcinoma7
CDKN2A p16 Expression	(prognostic)	Prognostic	B	Supports Better Outcome	4	accepted	EID695 p16 positivity, as a surrogate marker for HPV-associated HNSSC was a favorable prognostic marker in recurrent or metastatic carcinoma. PMID 24799460 · Argiris et al., 2014 · Open in CIViC	civic
CDKN2A p16 Expression	(prognostic)	Prognostic	B	Supports Better Outcome	3	accepted	EID804 Patients from three studies (RTOG 0129, 0234, and 0522; 85, 95 and 142 patients, respectively) were retrospectively analyzed for p16 (CDKN2A) expression (IHC) and HPV-high risk status (ISH). p16 expre… (full text at CIViC) PMID 25267748 · Chung et al., 2014 · Open in CIViC	civic
CDKN2A p16 Expression

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Lung Non-Small Cell Carcinoma1
CDKN2A p16 Expression	(prognostic)	Prognostic	B	Supports Poor Outcome	2	accepted	EID1314 In a cohort of 73 patients with stage I or stage II NSCLC it was discovered that the CDKN2A protein (p16-INK4A) retrospectively evaluated via IHC was associated with adverse outcomes (p=0.004). PMID 22619677 · Zhao et al., 2012 · Open in CIViC	civic

Malignant Oropharyngeal Neoplasm2
CDKN2A p16 Expression	(prognostic)	Prognostic	A	Supports Better Outcome	4	accepted	EID758 720 patients with stage III/IV oropharyngeal cancer were retrospectively analyzed for p16 and HPV status. p16 and HPV-positivity correlated well and both showed improved overall-survival compared to p… (full text at CIViC) PMID 20530316 · Ang et al., 2010 · Open in CIViC	civic
CDKN2A p16 Expression	Cetuximab	Predictive	B	Does Not Support Resistance	4	accepted	EID759 This study shows that benefit of EGFR inhibition in addition to radiotherapy was independent of p16/HPV status. 182 patients were evaluated. PMID 26712222 · Rosenthal et al., 2016 · Open in CIViC	civic

Sarcoma1
CDKN2A p16 Expression	Palbociclib	Predictive	D	Supports Resistance	4	submitted	EID4873 A preclinical study to explore the efficacy of CDK4/6 inhibition with palbociclib, in a panel of sarcoma cell lines and sarcoma tumor xenografts (PDXs). The responsiveness of these cell lines/PDX corr… (full text at CIViC) PMID 26528855 · Perez et al., 2015 · Open in CIViC	civic